Latest News

Vyriad and Sanford Health begin Phase I viro-immunotherapy trial

US-based biopharmaceutical firm Vyriad has initiated a clinical trial at integrated health system Sanford Health to evaluate a genetically engineered virus for destroying therapy-resistant tumours. ...

Vyriad and Sanford Health begin Phase I viro-immunotherapy trial

BMS Phase III’s combination trial for RCC meets one co-primary endpoint

Bristol-Myers Squibb (BMS) has reported top-line results from the Phase III CheckMate -214 clinical trial of Opdivo (nivolumab) and Yervoy (ipilimumab) combination to treat advanced or...

BMS Phase III’s combination trial for RCC meets one co-primary endpoint

Researchers demonstrate use of breast cancer drug to shrink brain tumours

Researchers from the University of Queensland’s Institute for Molecular Bioscience in Australia and the Fred Hutchinson Cancer Research Centre in the US have conducted a clinical trial to...

Researchers demonstrate use of breast cancer drug to shrink brain tumours

PCI Biotech starts dosing in Phase I extension study for bile duct cancer

Norwegian biopharmaceutical firm PCI Biotech has started dosing patients in a Phase I extension study with fimaCHEM to treat inoperable perihilar bile duct...

PCI Biotech starts dosing in Phase I extension study for bile duct cancer

University of Southampton investigates Acerta’s lymphoma drug

University of Southampton investigates Acerta’s lymphoma drug

Cyclodextrin slows NPC progression in new Washington University trial

Cyclodextrin slows NPC progression in new Washington University trial

Chiasma and FDA agree on new Phase III trial design for acromegaly drug

The US Food and Drug Administration (FDA) has agreed on biopharmaceutical firm Chiasma’s new Phase III clinical trial (OPTIMAL) design to evaluate its octreotide capsules product candidate...

Chiasma and FDA agree on new Phase III trial design for acromegaly drug

Viamet reports positive Phase II data for vulvovaginal candidiasis drug

Viamet Pharmaceuticals has reported positive results from a Phase II clinical trial (REVIVE) of VT-1161 to treat recurrent vulvovaginal candidiasis (RVVC)...

Viamet reports positive Phase II data for vulvovaginal candidiasis drug

Immunicum starts enrolment in US for Phase II oncology trial

Swedish biopharmaceutical firm Immunicum has started patient enrolment in the US for the ongoing Phase II MERECA clinical trial of its drug candidate ilixadencel to treat renal cell...

Immunicum starts enrolment in US for Phase II oncology trial

UK researchers report positive data from new diabetes trial

UK researchers report positive data from new diabetes trial

Deals this week: HitGen, Calithera Biosciences, Esperion Therapeutics

HitGen has signed an agreement with LEO Pharma to use its advanced technology platform to discover new small...

Deals this week: HitGen, Calithera Biosciences, Esperion Therapeutics

M&As this week: SELLAS Life Sciences Group, Cempra

SELLAS Life Sciences Group has signed a definitive agreement to merge with Galena...

M&As this week: SELLAS Life Sciences Group, Cempra

Biotecnol and Cancer Research UK to assess Tb535H for solid tumours

Immune-oncology firm Biotecnol and Cancer Research UK have entered a collaboration agreement to evaluate Tb535H in clinical trials to treat patients suffering from solid...

Biotecnol and Cancer Research UK to assess Tb535H for solid tumours

Allegro’s Phase IIb stage 2 trial for DME drug meets primary endpoint

Biotechnology firm Allegro Ophthalmics has reported positive top-line results from the DEL MAR Phase IIb stage 2 clinical trial of luminate as a sequential therapy to treat diabetic macular...

Allegro’s Phase IIb stage 2 trial for DME drug meets primary endpoint

TapImmune broadens TPIV200’s Phase II trial for ovarian cancer

TapImmune broadens TPIV200’s Phase II trial for ovarian cancer

WIN Consortium to conduct targeted tri-therapy trial for NSCLC

French non-profit healthcare network WIN Consortium (WIN) is set to conduct a clinical trial (SPRING) of a new three targeted therapies combination as first-line treatment for patients...

WIN Consortium to conduct targeted tri-therapy trial for NSCLC

Zynerba’s Phase II epilepsy trial of ZYN002 fails to meet primary endpoint

Zynerba Pharmaceuticals has reported top-line results from the Phase II STAR 1 clinical trial of ZYN002 to treat adult epilepsy patients with focal...

Zynerba’s Phase II epilepsy trial of ZYN002 fails to meet primary endpoint

Amylyx begins dosing in Phase II trial of AMX0035 for ALS

Amylyx Pharmaceuticals has begun dosing patients in the Phase II CENTAUR clinical trial of its therapeutic candidate, AMX0035, to treat those with amyotrophic lateral sclerosis...

Amylyx begins dosing in Phase II trial of AMX0035 for ALS

Rebiotix starts enrolment in Phase III trial of RBX2660 for C. diff infection

Rebiotix starts enrolment in Phase III trial of RBX2660 for C. diff infection

MyoKardia’s Phase II trial for oHCM drug meets endpoints

MyoKardia has reported positive top-line results from the first cohort of its Phase II PIONEER-HCM clinical trial of mavacamten in patients with symptomatic, obstructive hypertrophic...

MyoKardia’s Phase II trial for oHCM drug meets endpoints

Calithera begins Phase II trial of CB-839 to treat renal cell carcinoma

Pharmaceutical firm Calithera Biosciences has begun a Phase II clinical trial of CB-839 in combination with Afinitor (everolimus)‎ for the treatment of patients with renal cell carcinoma...

Calithera begins Phase II trial of CB-839 to treat renal cell carcinoma